DK0750509T4 - Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme - Google Patents

Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme

Info

Publication number
DK0750509T4
DK0750509T4 DK95912666T DK95912666T DK0750509T4 DK 0750509 T4 DK0750509 T4 DK 0750509T4 DK 95912666 T DK95912666 T DK 95912666T DK 95912666 T DK95912666 T DK 95912666T DK 0750509 T4 DK0750509 T4 DK 0750509T4
Authority
DK
Denmark
Prior art keywords
autoimmune
preparation
treatment
antagonists
autoimmune diseases
Prior art date
Application number
DK95912666T
Other languages
Danish (da)
English (en)
Other versions
DK0750509T3 (da
Inventor
Samuel Goldman
John P Leonard
Richard O'hara Jr
Original Assignee
Genetics Inst Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0750509(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst Llc filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of DK0750509T3 publication Critical patent/DK0750509T3/da
Publication of DK0750509T4 publication Critical patent/DK0750509T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95912666T 1994-03-14 1995-03-07 Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme DK0750509T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14
PCT/US1995/002550 WO1995024918A1 (en) 1994-03-14 1995-03-07 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DK0750509T3 DK0750509T3 (da) 2002-07-08
DK0750509T4 true DK0750509T4 (da) 2006-10-16

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95912666T DK0750509T4 (da) 1994-03-14 1995-03-07 Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme

Country Status (14)

Country Link
US (1) US6338848B1 (de)
EP (4) EP2201959A3 (de)
JP (1) JP3798426B2 (de)
AT (1) ATE217533T1 (de)
AU (1) AU689236B2 (de)
CA (1) CA2185565C (de)
DE (1) DE69526728T3 (de)
DK (1) DK0750509T4 (de)
ES (1) ES2173953T5 (de)
IL (1) IL112677A (de)
PT (1) PT750509E (de)
TW (1) TW400233B (de)
WO (1) WO1995024918A1 (de)
ZA (1) ZA95960B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
ES2213209T3 (es) * 1996-11-15 2004-08-16 Kennedy Institute Of Rheumatology Supresion de tnfalfa e il-12 en terapia.
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
ATE357459T1 (de) 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
EP1336654A1 (de) * 1998-12-09 2003-08-20 Protein Design Labs, Inc. Verfahren zur Behandlung von Psoriasis mittels anti-gamma Interferon Antikörpers
KR100659007B1 (ko) 1999-02-10 2007-02-28 미츠비시 웰파마 가부시키가이샤 아미드 화합물 및 그 의약으로서의 용도
KR20130105766A (ko) * 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
CA2548179A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
WO2005085866A1 (en) * 2004-02-27 2005-09-15 Novartis Ag Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
DK2299275T3 (en) * 2004-07-30 2018-05-07 Adeza Biomedical Corp Classification of oncofetal fetronectin level for pregnancy-related indications
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
CN102245205A (zh) * 2008-09-30 2011-11-16 贝勒研究院 用于减少b-辅助性t细胞以治疗自身免疫疾病的方法
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2011032148A1 (en) 2009-09-14 2011-03-17 Abbott Laboratories Methods for treating psoriasis
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012050829A2 (en) * 2010-09-28 2012-04-19 Neumedicines, Inc. Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
NO2709651T3 (de) * 2011-05-19 2018-03-03
EP2736530B1 (de) * 2011-07-27 2018-06-06 Neumedicines, Inc Verwendung von il-12 zur erzeugung von endogenem erythropoetin
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
EP2970459A2 (de) 2013-03-15 2016-01-20 AbbVie Inc. Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (de) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0790308T3 (da) * 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (de) † 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Interleukin-12 Rezeptoren und Antikörper
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
KR20000076420A (ko) * 1997-03-18 2000-12-26 스타르크, 카르크 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及***、光网络单元

Also Published As

Publication number Publication date
ZA95960B (en) 1995-10-10
AU1974995A (en) 1995-10-03
EP2201959A2 (de) 2010-06-30
DE69526728T2 (de) 2002-11-21
EP0750509A1 (de) 1997-01-02
EP1179348A2 (de) 2002-02-13
AU689236B2 (en) 1998-03-26
CA2185565C (en) 2009-02-03
CA2185565A1 (en) 1995-09-21
EP0750509B1 (de) 2002-05-15
ES2173953T5 (es) 2007-03-01
IL112677A (en) 2000-01-31
EP2311484A1 (de) 2011-04-20
DK0750509T3 (da) 2002-07-08
JPH09510444A (ja) 1997-10-21
ATE217533T1 (de) 2002-06-15
EP1179348A3 (de) 2003-12-03
IL112677A0 (en) 1995-05-26
EP0750509B2 (de) 2006-06-14
ES2173953T3 (es) 2002-11-01
EP2201959A3 (de) 2011-03-16
DE69526728T3 (de) 2007-01-04
JP3798426B2 (ja) 2006-07-19
US6338848B1 (en) 2002-01-15
PT750509E (pt) 2002-08-30
DE69526728D1 (de) 2002-06-20
TW400233B (en) 2000-08-01
WO1995024918A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
DK0750509T3 (da) Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme
Saxne et al. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis
ATE411029T1 (de) Estrogene als antimitotika
ATE183087T1 (de) Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
WO1994007535A3 (en) Labelled interleukin-8 and medical uses thereof
DK0707487T3 (da) Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser
DK2795A (da) Fremgangsmåde til fremstilling af 4-substituerede 3-(1'-hydroxyethyl)-azetidin-2-oner samt azetidin-2-on-derivat
IT1229506B (it) Polimero dell'acido acrilico esente da solventi residui e procedimento per la sua preparazione.
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
DK0413329T3 (da) 5-methyl-isoxazol-4-carboxylsyreanilider og 2-hydroxyethyliden-cyaneddikesyreanilider til behandling af øjensygdomme
NO177148C (no) Fluorelastomerer basert på vinylidenfluorid, heksafluorpropen og tetrafluoretylen, samt anvendelse av slike
Schorlemmer et al. Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis
Kirk et al. A brief inservice training strategy to increase levels of empathy of psychiatric nursing personnel.
Rosenbaum Treating hair pulling in a 7-year-old male: Modified habit reversal for use in pediatric settings
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
IT7950444A0 (it) N-(1-metil 2-pirrolidinilmetil) 2,3dimetossi-5-metilsolfamoil benzammide e suoi derivati utili per il trattamento dei disturbi dell'appa rato urinario e procedimento di preparazione
IT8820274A0 (it) Procedimento per la sintesi di esteri ed ammidi dell'acido ossalico.
Finnerty-Fried Adapting rehabilitation counseling for older persons.
Sakamoto et al. A Case Report of Multiple Tendon Xanthomas
Himle et al. Recent research on social support and burnout: Implications for behavior therapy.
IT8421534A0 (it) Esteri dell'acido acetico eterociclici e relativo procedimento di fabbricazione.
Heye et al. Investigation of use of alternative treatment methods by patients with rheumatoid arthritis
IT7924227A0 (it) Metodo per la terapia dell'artrite reumatoide e formulazioni farmaceutiche idonee allo scopo.
Dolapchieva Computer-Assisted Morphometric Study on the Axons and Myelin Sheaths Areas of Developing Myelin Fibres in Peripheral Nerves of the Rabbit
Tohyama et al. Long-Term Functional Prognosis and CT Findings of Patients with Crush Syndrome from the Hanshin-Awaji Earthquake